{"classes":[{"categories":[{"measurements":[{"comment":"not enough events to calculate","groupId":"OG000","lowerLimit":"3.5","upperLimit":"NA","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as number of months between start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurs first. Disease progression was determined using IMWG-URC per investigator. The duration of PFS was right-censored for participants who met 1 of the following conditions:\n\n* 1\\) starting a new anticancer therapy before documentation of disease progression or death;\n* 2\\) death or disease progression immediately after more than 1 consecutively missed disease assessment visit or;\n* 3\\) alive without documentation of disease progression before the data cutoff date.\n\n  95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.","id":"OG000","title":"Phase 2 300 mg 2/7 Schedule"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Day 1 up to 14.1 months","title":"Kaplan-Meier Estimates for Progression-free Survival (PFS) as Assessed by Investigator During Phase 2","type":"SECONDARY","unitOfMeasure":"months"}